ArticlemAbs2026
NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-concentration formulations of monoclonal antibodies (mAbs) are required for subcutaneous administration but are frequently challenging to develop due to elevated viscosity and colloidal instability. These properties are governed by mAb-mAb interactions that are regulated by additional mAb-excipient interactions. These ultra-weak interactions remain difficult to characterize using conventional techniques. Here, we combined nuclear magnetic resonance (NMR) spectroscopy with rheometry and dynamic light scattering to investigate mAb interactions under formulation-relevant conditions. Rheological measurements showed that, in the case of the chosen mAb, the excipients arginine and lysine strongly reduce the macroscopic viscosity, whereas other excipients display a moderate effect by themselves. Characterization of the mAb oligomeric state by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.